ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment

Author(s):Show less -

Moretti Rebecchi, Ivanise Marina ^[1] ; Rodrigues, Alice Cristina ^[1] ; Arazi, Simone Sorkin ^[1] ; Genuigir, Fabiana Dalla Vecchia ^[1] ; Vieira Willrich, Maria Alice ^[1] ; Hirata, Mario Hiroyuki ^[1] ; Soares, Sarah Aparecida ^[1] ; Bertolami, Marcelo Chiara ^[2] ; Faludi, Andre Arpad ^[2] ; Bernik, Marcia Martins Silveira ^[3] ; Dorea, Egidio Lima ^[3] ; Zaidan Dagli, Maria Lucia ^[4] ; Avanzo, Jose Luis ^[4] ; Crespo Hirata, Rosario Dominguez ^[1]

Affiliation

^[1] Univ Sao Paulo, Fac Pharmaceut Sci, BR-05508900 Sao Paulo - Brazil

^[2] Inst Dante Pazzanese Cardiol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo - Brazil

^[4] Univ Sao Paulo, Fac Vet Med & Anim Sci, BR-05508900 Sao Paulo - Brazil

• Document type: Journal article
• Source: Biochemical Pharmacology; v. 77, n. 1, p. 66-75, JAN 1 2009.
• Web of Science Citations: 23

Abstract

This study investigated the effects of atorvastatin on ABCB1 and ABCC1 mRNA expression on peripheral blood mononuclear cells (PBMC) and their relationship with gene polymorphisms and lowering-cholesterol response. one hundred and thirty-six individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). Blood samples were collected for serum lipids and apolipoproteins measurements and DNA and RNA extraction. ABCB1 (C3435T and G2677T/A) and ABCC1 (G2012T) gene polymorphisms were identified by polymerase chain reaction-restriction (PCR)-RFLP and mRNA expression was measured in peripheral blood mononuclear cells by singleplex real-time PCR. ABCB1 polymorphisms were associated with risk for coronary artery disease (CAD) (p < 0.05). After atorvastatin treatment, both ABCB1 and ABCC1 genes showed 50% reduction of the mRNA expression (p < 0.05). Reduction of ABCB1 expression was associated with ABCB1 G2677T/A polymorphism (p = 0.039). Basal ABCB1 mRNA in the lower quartile (<0.024) was associated with lower reduction rate of serum low-density lipoprotein (LDL) cholesterol (33.4 +/- 12.4%) and apolipoprotein B (apoB) (17.0 +/- 31.3%) when compared with the higher quartile (>0.085: LDL-c = 40.3 +/- 14.3%; apoB = 32.5 +/- 10.7%; p < 0.05). ABCB1 substrates or inhibitors did not affect the baseline expression, while ABCB1 inhibitors reversed the effects of atorvastatin on both ABCB1 and ABCC1 transporters. In conclusion, ABCB1 and ABCC1 mRNA levels in PBMC are modulated by atorvastatin and ABCB1 G2677T/A polymorphism. and ABCB1 baseline expression is related to differences in serum LDL cholesterol and apoB in response to atorvastatin. (C) 2008 Elsevier Inc. All rights reserved. (AU)